SEC Form SC 13G filed by Perspective Therapeutics Inc.

11/7/24 9:12:21 AM ET

Medical/Dental Instruments

Health Care

Get the next $CATX alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 PERSPECTIVE THERAPEUTICS INC COMMON STOCK Cusip #46489V302 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46489V302 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,504,150 Item 6: 0 Item 7: 5,504,822 Item 8: 0 Item 9: 5,504,822 Item 11: 8.164% Item 12: HC Cusip #46489V302 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,504,822 Item 8: 0 Item 9: 5,504,822 Item 11: 8.164% Item 12: IN Item 1(a). Name of Issuer: PERSPECTIVE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2401 ELLIOTT AVENUE, SUITE 320 SEATTLE, WA 98121 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 46489V302 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,504,822 (b) Percent of Class: 8.164% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,504,822 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PERSPECTIVE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of PERSPECTIVE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 6, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 6, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PERSPECTIVE THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CATX alert in real time by email

Recent Analyst Ratings for

$CATX

Date	Price Target	Rating	Analyst
3/13/2025	$10.00	Buy	H.C. Wainwright
3/7/2025	$15.00	Sector Outperform	Scotiabank
11/25/2024	$24.00 → $5.00	Buy → Neutral	BofA Securities
10/24/2024	$20.00	Buy	UBS
10/1/2024	$25.00	Outperform	Wedbush
9/25/2024	$21.00	Buy	Truist
7/25/2024	$24.00	Buy	BofA Securities
5/9/2024		Overweight	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G filed by Perspective Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $CATX

$CATX Press Releases

Fastest customizable press release news feed in the world

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

$CATX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

$CATX SEC Filings

SEC Form SD filed by Perspective Therapeutics Inc.

SEC Form 10-Q filed by Perspective Therapeutics Inc.

Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$CATX Leadership Updates

Live Leadership Updates

$CATX Financials

Live finance-specific insights

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

$CATX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

$CATX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

Scotiabank initiated coverage on Perspective Therapeutics with a new price target

Perspective Therapeutics downgraded by BofA Securities with a new price target

$CATX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Perspective Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

Recent Analyst Ratings for
$CATX

$CATX
Press Releases

$CATX
Insider Purchases

$CATX
SEC Filings

$CATX
Leadership Updates

$CATX
Financials

$CATX
Insider Trading

$CATX
Analyst Ratings

$CATX
Large Ownership Changes